ProCE Banner Activity

Phase III SOLE: Continuous vs Intermittent Letrozole After Adjuvant Endocrine Therapy in Early HR+ Breast Cancer

Slideset Download
Conference Coverage
Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing.

Released: June 08, 2017

Expiration: June 07, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology